- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Venus Remedies Limited — Board Meeting, 20-07-2026: Outcome of Board Meeting
20-07-2026 | 06:37 pm
20-07-2026 | 06:37 pm
Venus Remedies' board approved Q1 consolidated results: Revenue ₹178.86 Cr, Net Profit ₹22.97 Cr, EPS ₹17.18. They also approved revisions to the MOA for updated business objectives (pending shareholder approval). The company is supporting its financially challenged German subsidiary, Venus Pharma GmbH.
No comments yet. Be the first to comment!